Clinical trial of MBX 1416 for Post-Bariatric Hypoglycemia begins
The first participant has been dosed in MBX Biosciences’ Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like...
top of page
Browse by category
Search
MBX Biosciences gains FDA clearance to study MBX 1416 for post-bariatric hypoglycaemia
MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide (PEP) therapeutics to treat an array...
Browse by tag
bottom of page